drugset / Trial / NCT07012486

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

NCT07012486

Phase 0 Recruiting 30 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.

Timeline

Start
2025-06
Primary completion
2026-05
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 20 mg Oral
Comparator Minoxidil Small molecule 5 % Topical

Indications